Autopsy report · NCT02608268

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

“Business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 6 years 9 months before it stopped.
• 252 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Advanced Malignancies

Interventions

MBG453; PDR001; Decitabine

Participants

252

Sites

14

Countries

Canada, Italy, Japan, Netherlands, Singapore, South Korea, Switzerland, Taiwan, United States

Trials that died the same way

• A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
  “Business Reason” (94% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (88% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (87% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (85% match in meaning)
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
  “for business reasons” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.